We are analyzing https://link.springer.com/article/10.1007/bf02850321.

Title:
Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: A 1-year randomized clinical trial | Advances in Therapy
Description:
This study was conducted to evaluate the efficacy and tolerability of rosiglitazone in the treatment of patients with secondary oral antidiabetic drug (OAD) failure and to directly compare its use with bedtime insulin. A total of 112 Chinese patients with type 2 diabetes and conventional OAD failure were recruited. Patients were randomly assigned to treatment with rosiglitazone or bedtime isophane insulin; they continued to take their original oral antidiabetic drugs. Glycemic index, other clinical profiles, and tolerability were assessed during treatment and 1 y after add-on treatment was provided. Among the 112 patients, mean age (±SD) was 58.2±11.0 y (median, 58 y; range, 37 to 84 y). Both rosiglitazone (n=56) and insulin (n=56) significantly improved fasting glucose (2.4 and 3.7 mmol/L, respectively) and hemoglobin A1c concentrations (1.1% and 1.3%, respectively). Both therapies increased body mass index after 1 y of treatment (0.9 and 0.8 kg/m2, respectively). Only rosiglitazone increased high-density lipoprotein cholesterol concentrations (0.1 mmol/L). Four patients (7.1 %) who were given rosiglitazone developed adverse effects (2, ankle edema, and 2, gastrointestinal disturbance). Six insulin-treated patients (10.7%) described adverse effects (5, early morning hypoglycemia, and 1, anxiety). Investigators concluded that in Chinese patients with type 2 diabetes and secondary conventional OAD failure, 1 y of treatment with rosiglitazone or bed-time insulin added to the regular regimen resulted in similar improvements in glycemic control. Rosiglitazone was also associated with improved high-density lipoprotein cholesterol levels. The addition of rosiglitazone may offer a safe and effective alternative to bedtime insulin treatment.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Insurance
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

article, cas, google, scholar, pubmed, insulin, rosiglitazone, patients, diabetes, type, treatment, therapy, oral, bedtime, randomized, failure, access, med, antidiabetic, drug, mellitus, privacy, cookies, content, clinical, effects, thiazolidinediones, combination, publish, search, conventional, tsang, mbchb, chinese, control, addition, open, metab, care, hospital, data, information, log, journal, research, versus, wai, efficacy, secondary, oad,

Topics {✒️}

low-density lipoprotein cholesterol month download article/chapter diabetic-related genomic loci randomized placebo-controlled trials peroxisome proliferator-activated receptors bed-time insulin added oral anti-diabetic drugs cell-surface glut4 full article pdf related subjects type ii diabetes adverse effects line diabetes therapy privacy choices/manage cookies conventional oad failure hemoglobin a1c concentrations increased insulin binding randomized controlled trial existing diabetes mellitus oral hypoglycemic agents oral agents fail trends endocrinol metab article advances rosiglitazone combination therapy enhances insulin action low-dose rosiglitazone check access instant access post-prandial glucose poor glucose control vildagliptin versus pioglitazone drug saf bedtime isophane insulin bedtime insulin regimens double-blind trial european economic area early morning hypoglycemia regular regimen resulted road tai po kan mphil & hamish potent insulin sensitizer conditions privacy policy 112 chinese patients chinese patients type 2 diabetes sulfonylurea combination therapy metformin combination therapy ah nethersole hospital article log current clinical evidence

Questions {❓}

Hepatotoxicity with thiazolidinediones: is it a class effect?
Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: A 1-year randomized clinical trial
         description:This study was conducted to evaluate the efficacy and tolerability of rosiglitazone in the treatment of patients with secondary oral antidiabetic drug (OAD) failure and to directly compare its use with bedtime insulin. A total of 112 Chinese patients with type 2 diabetes and conventional OAD failure were recruited. Patients were randomly assigned to treatment with rosiglitazone or bedtime isophane insulin; they continued to take their original oral antidiabetic drugs. Glycemic index, other clinical profiles, and tolerability were assessed during treatment and 1 y after add-on treatment was provided. Among the 112 patients, mean age (±SD) was 58.2±11.0 y (median, 58 y; range, 37 to 84 y). Both rosiglitazone (n=56) and insulin (n=56) significantly improved fasting glucose (2.4 and 3.7 mmol/L, respectively) and hemoglobin A1c concentrations (1.1% and 1.3%, respectively). Both therapies increased body mass index after 1 y of treatment (0.9 and 0.8 kg/m2, respectively). Only rosiglitazone increased high-density lipoprotein cholesterol concentrations (0.1 mmol/L). Four patients (7.1 %) who were given rosiglitazone developed adverse effects (2, ankle edema, and 2, gastrointestinal disturbance). Six insulin-treated patients (10.7%) described adverse effects (5, early morning hypoglycemia, and 1, anxiety). Investigators concluded that in Chinese patients with type 2 diabetes and secondary conventional OAD failure, 1 y of treatment with rosiglitazone or bed-time insulin added to the regular regimen resulted in similar improvements in glycemic control. Rosiglitazone was also associated with improved high-density lipoprotein cholesterol levels. The addition of rosiglitazone may offer a safe and effective alternative to bedtime insulin treatment.
         datePublished:
         dateModified:
         pageStart:799
         pageEnd:808
         sameAs:https://doi.org/10.1007/BF02850321
         keywords:
            rosiglitazone
            insulin
            oral antidiabetic drug
            failure
            Chinese
            Internal Medicine
            Oncology
            Cardiology
            Rheumatology
            Endocrinology
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Advances in Therapy
            issn:
               1865-8652
               0741-238X
            volumeNumber:23
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Healthcare Communications
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Gary T. C. Ko
               affiliation:
                     name:AH Nethersole Hospital
                     address:
                        name:Department of Medicine, AH Nethersole Hospital, Hong Kong
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Patrick C. C. Tsang
               affiliation:
                     name:AH Nethersole Hospital
                     address:
                        name:Department of Medicine, AH Nethersole Hospital, Hong Kong
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hendena P. S. Wai
               affiliation:
                     name:AH Nethersole Hospital
                     address:
                        name:St. Teresa’s Hospital, AH Nethersole Hospital, Hong Kong, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eva C. Y. Kan
               affiliation:
                     name:AH Nethersole Hospital
                     address:
                        name:Department of Medicine, AH Nethersole Hospital, Hong Kong, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hamish C. K. Chan
               affiliation:
                     name:AH Nethersole Hospital
                     address:
                        name:Department of Medicine, AH Nethersole Hospital, Hong Kong, China
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: A 1-year randomized clinical trial
      description:This study was conducted to evaluate the efficacy and tolerability of rosiglitazone in the treatment of patients with secondary oral antidiabetic drug (OAD) failure and to directly compare its use with bedtime insulin. A total of 112 Chinese patients with type 2 diabetes and conventional OAD failure were recruited. Patients were randomly assigned to treatment with rosiglitazone or bedtime isophane insulin; they continued to take their original oral antidiabetic drugs. Glycemic index, other clinical profiles, and tolerability were assessed during treatment and 1 y after add-on treatment was provided. Among the 112 patients, mean age (±SD) was 58.2±11.0 y (median, 58 y; range, 37 to 84 y). Both rosiglitazone (n=56) and insulin (n=56) significantly improved fasting glucose (2.4 and 3.7 mmol/L, respectively) and hemoglobin A1c concentrations (1.1% and 1.3%, respectively). Both therapies increased body mass index after 1 y of treatment (0.9 and 0.8 kg/m2, respectively). Only rosiglitazone increased high-density lipoprotein cholesterol concentrations (0.1 mmol/L). Four patients (7.1 %) who were given rosiglitazone developed adverse effects (2, ankle edema, and 2, gastrointestinal disturbance). Six insulin-treated patients (10.7%) described adverse effects (5, early morning hypoglycemia, and 1, anxiety). Investigators concluded that in Chinese patients with type 2 diabetes and secondary conventional OAD failure, 1 y of treatment with rosiglitazone or bed-time insulin added to the regular regimen resulted in similar improvements in glycemic control. Rosiglitazone was also associated with improved high-density lipoprotein cholesterol levels. The addition of rosiglitazone may offer a safe and effective alternative to bedtime insulin treatment.
      datePublished:
      dateModified:
      pageStart:799
      pageEnd:808
      sameAs:https://doi.org/10.1007/BF02850321
      keywords:
         rosiglitazone
         insulin
         oral antidiabetic drug
         failure
         Chinese
         Internal Medicine
         Oncology
         Cardiology
         Rheumatology
         Endocrinology
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Advances in Therapy
         issn:
            1865-8652
            0741-238X
         volumeNumber:23
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Healthcare Communications
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Gary T. C. Ko
            affiliation:
                  name:AH Nethersole Hospital
                  address:
                     name:Department of Medicine, AH Nethersole Hospital, Hong Kong
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Patrick C. C. Tsang
            affiliation:
                  name:AH Nethersole Hospital
                  address:
                     name:Department of Medicine, AH Nethersole Hospital, Hong Kong
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hendena P. S. Wai
            affiliation:
                  name:AH Nethersole Hospital
                  address:
                     name:St. Teresa’s Hospital, AH Nethersole Hospital, Hong Kong, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eva C. Y. Kan
            affiliation:
                  name:AH Nethersole Hospital
                  address:
                     name:Department of Medicine, AH Nethersole Hospital, Hong Kong, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hamish C. K. Chan
            affiliation:
                  name:AH Nethersole Hospital
                  address:
                     name:Department of Medicine, AH Nethersole Hospital, Hong Kong, China
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Advances in Therapy
      issn:
         1865-8652
         0741-238X
      volumeNumber:23
Organization:
      name:Springer Healthcare Communications
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:AH Nethersole Hospital
      address:
         name:Department of Medicine, AH Nethersole Hospital, Hong Kong
         type:PostalAddress
      name:AH Nethersole Hospital
      address:
         name:Department of Medicine, AH Nethersole Hospital, Hong Kong
         type:PostalAddress
      name:AH Nethersole Hospital
      address:
         name:St. Teresa’s Hospital, AH Nethersole Hospital, Hong Kong, China
         type:PostalAddress
      name:AH Nethersole Hospital
      address:
         name:Department of Medicine, AH Nethersole Hospital, Hong Kong, China
         type:PostalAddress
      name:AH Nethersole Hospital
      address:
         name:Department of Medicine, AH Nethersole Hospital, Hong Kong, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Gary T. C. Ko
      affiliation:
            name:AH Nethersole Hospital
            address:
               name:Department of Medicine, AH Nethersole Hospital, Hong Kong
               type:PostalAddress
            type:Organization
      name:Patrick C. C. Tsang
      affiliation:
            name:AH Nethersole Hospital
            address:
               name:Department of Medicine, AH Nethersole Hospital, Hong Kong
               type:PostalAddress
            type:Organization
      name:Hendena P. S. Wai
      affiliation:
            name:AH Nethersole Hospital
            address:
               name:St. Teresa’s Hospital, AH Nethersole Hospital, Hong Kong, China
               type:PostalAddress
            type:Organization
      name:Eva C. Y. Kan
      affiliation:
            name:AH Nethersole Hospital
            address:
               name:Department of Medicine, AH Nethersole Hospital, Hong Kong, China
               type:PostalAddress
            type:Organization
      name:Hamish C. K. Chan
      affiliation:
            name:AH Nethersole Hospital
            address:
               name:Department of Medicine, AH Nethersole Hospital, Hong Kong, China
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Medicine, AH Nethersole Hospital, Hong Kong
      name:Department of Medicine, AH Nethersole Hospital, Hong Kong
      name:St. Teresa’s Hospital, AH Nethersole Hospital, Hong Kong, China
      name:Department of Medicine, AH Nethersole Hospital, Hong Kong, China
      name:Department of Medicine, AH Nethersole Hospital, Hong Kong, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(106)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.94s.

LINK . SPRINGER . COM {}